Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angiotensin II receptor type 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Angiotensin II receptor type 1. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-012676-27 Sponsor Protocol Number: FemExp-I Start Date*: 2010-01-24
    Sponsor Name:Wallenberg laboratory
    Full Title: Femoral-Express-I
    Medical condition: Peripheral artery disease. Patients due for by-pass surgery of lower extremity arteries.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10034638 Peripheral vascular disorders NEC HLT
    12.0 10003611 Atherosclerosis of arteries of the extremities, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003991-37 Sponsor Protocol Number: AGO/2006/009 Start Date*: 2006-12-13
    Sponsor Name:University Hospital Gent
    Full Title: Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
    Medical condition: Marfan syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10026829 Marfan's syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003262-17 Sponsor Protocol Number: AG-1-2007. Start Date*: 2008-08-13
    Sponsor Name:University Hospital Magdeburg
    Full Title: Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation
    Medical condition: Blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules compared to placebo in patients with persistent/permanent atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007881-45 Sponsor Protocol Number: SPP100ANL02T Start Date*: 2009-03-12
    Sponsor Name:University Medical Center Groningen
    Full Title: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients w...
    Medical condition: Patients with chronic heart failure and reduced glomerular filtration rate.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003175-19 Sponsor Protocol Number: U1111-1206-7541 Start Date*: 2019-11-28
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Renal effects of treatment with Empagliflozin alone or in combination with Semaglutide in patients with type 2 diabetes and albuminuria - A double blinded, randomised, placebo controlled, parallel...
    Medical condition: Type 2 diabetes with renal complications
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001191-12 Sponsor Protocol Number: Salt og Cirrhose Start Date*: 2005-07-06
    Sponsor Name:Odense Universitetshospital
    Full Title: Forebyggelse af inkompenseret levercirrose med Losartan Et prospektivt randomiseret dobbeltblindet lantidsstudie
    Medical condition: Alkoholisk levercirrose. Fibrosedannelse og senere cirrose i leveren efter en årrække med øget indtag/misbrug af alkohol. Komplikationer ses i form af inkomensation med ascites, oesofagusvaricer og...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001190-25 Sponsor Protocol Number: A6291015 Start Date*: 2004-12-17
    Sponsor Name:Pfizer Ltd
    Full Title: A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensi...
    Medical condition: Diabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations). MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002878-50 Sponsor Protocol Number: NN9535-4321 Start Date*: 2019-04-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) SK (Completed) BG (Completed) DE (Completed) ES (Ongoing) FR (Completed) PL (Completed) BE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019798-13 Sponsor Protocol Number: MB102-077 Start Date*: 2011-03-04
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Co...
    Medical condition: Type 2 diabetes with inadequate glycemic control and inadequately controlled hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) FI (Completed) DK (Completed) IE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-005710-11 Sponsor Protocol Number: SNOXE36C301 Start Date*: 2012-02-15
    Sponsor Name:NOXXON Pharma AG
    Full Title: A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.
    Medical condition: diabetes mellitus type II and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-019797-32 Sponsor Protocol Number: MB102-073 Start Date*: 2010-09-30
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately c...
    Medical condition: Men and women with type 2 diabetes, ages ≥ 18 to ≤ 89 years, who have type 2 diabetes with inadequately controlled hypertension.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    14.1 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) CZ (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000362-39 Sponsor Protocol Number: CSPP100A2243 Start Date*: 2005-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an a...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003610-41 Sponsor Protocol Number: CL2-78989-011 Start Date*: 2015-03-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Dose-response study of gevokizumab (S78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-bli...
    Medical condition: Diabetic kidney disease in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Completed) BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) SE (Completed) ES (Completed) PT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003962-14 Sponsor Protocol Number: BLO K022 Start Date*: 2004-12-16
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Candesartan "added" Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters. An open, non-controlled and multicentre trial
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002676-24 Sponsor Protocol Number: D1690C00023 Start Date*: 2015-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: An exploratory Phase II/III, randomized, double-blind, placebo controlled, parallel design study to evaluate the efficacy, safety and pharmacodynamics of dapagliflozin and dapagliflozin in combinat...
    Medical condition: CKD3 patients with type 2 diabetes mellitus and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005093-54 Sponsor Protocol Number: CV202-010 Start Date*: 2013-05-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Twostage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic...
    Medical condition: Diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003674-32 Sponsor Protocol Number: 1.1:12-6-2015 Start Date*: 2016-02-23
    Sponsor Name:Leiden University Medical Center
    Full Title: The effect of Telmisartan on inflammatory processes in the vascular wall of abdominal aortic aneurysms.
    Medical condition: Abdominal aortic aneurysm with an indication for elective open surgical repair.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003037-11 Sponsor Protocol Number: 21839 Start Date*: 2022-04-13
    Sponsor Name:Bayer AG
    Full Title: A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants wi...
    Medical condition: Chronic kidney disease in type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004545-34 Sponsor Protocol Number: AT10001 Start Date*: 2006-02-20
    Sponsor Name:Unit of Esophageal and Gastric Research Dep. of Molecular Medicine and Surgery Karolinska Institutet
    Full Title: Can Angiotensin II type 1 Receptor Inhibitor Be Used to Lower the Amount of Lipase and Amylase Level after Endoscopic Retrograde Cholangio-Pancreatography?
    Medical condition: The clinical diagnosis of acute pancreatitis is set by a combination of symptoms (abdominal pain) and increased blood levels of pancreatic enzymes (i.e. amylase and lipase). The most common complic...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 16 19:50:20 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA